Raelipskie Partnership’s AstraZeneca AZN Stock Holding History

Raelipskie Partnership’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.44M	Buy	+7,412	New	+$1.43M	0.61%	35

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Raelipskie Partnership's AZN Position: Q1 2026 in Review

Raelipskie Partnership opened a new position in AstraZeneca (AZN) in Q1 2026: 7,412 shares worth $1.44M. The stake represents 0.61% of the portfolio and ranks #35 among its holdings.

1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Raelipskie Partnership held 7,412 shares of AstraZeneca worth $1.44M as of Q1 2026.
AstraZeneca was a new Raelipskie Partnership position in Q1 2026.
AstraZeneca made up 0.61% of Raelipskie Partnership's portfolio in Q1 2026, its #35 holding.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Raelipskie Partnership's 13F filing for Q1 2026, filed 29 Apr 2026.